# Alamar Biosciences share price today (Alamar Biosciences, Inc., ALMR)

> Alamar Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ALMR · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/almr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $30.22
- Revenue (Jun 2026): $29.4 M (+82.1% on a year ago)
- Profit (Jun 2026): −$13.2 M
- Operating margin: −46.0% (+3.0 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Alamar Biosciences share price today? Alamar Biosciences, Inc.'s share price was $30.22 at the close on 3 November 2026. Since its first close in our records, on 24 April 2026, it has traded between $20 and $35, and at that close it sat 69% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. Over the last 6 months the share price moved +22% while the S&P 500 moved +6%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Alamar Biosciences pay? Alamar Biosciences, Inc. pays no dividend. In the last 4 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Alamar Biosciences on? Alamar Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Alamar Biosciences profitable? Alamar Biosciences, Inc. posted a net loss of $13.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $29.8 M. That loss is 44.9% of the quarter's revenue. ## How much revenue does Alamar Biosciences make, and is it growing? Alamar Biosciences, Inc. reported $29.4 M of revenue in the Jun 2026 quarter, +82.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 1 years it has grown 195.2% a year on average. The last full year, FY25, came in at $74.2 M. Recent pace: the last four quarters grew +90.5% on average, against 195.2% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Alamar Biosciences keep? Alamar Biosciences, Inc.'s operating margin was −46.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Across 2 years it has been between −197.2% and −42.2%. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Alamar Biosciences' profit turning into cash? Alamar Biosciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $53.6 M of cash, against −$29.8 M of profit. After $5.4 M of spending on assets, free cash was −$59.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Alamar Biosciences' cash go? Alamar Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $8.3 M on assets over the last 2 years. Averaged over those years that is 5.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $8.3 M over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Alamar Biosciences' P/E ratio, and how does it compare with its own history? Alamar Biosciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Alamar Biosciences, Inc. at 28.3× its FY25 revenue of $74.2 M. The P/E comes back here once profit turns positive. ## Is the Alamar Biosciences business getting better or worse? Alamar Biosciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Alamar Biosciences earn on its capital? Alamar Biosciences, Inc. earned a ROE of −39% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −40.2% net margin and 0.53× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −40.2% net margin × 0.53× asset turnover × 1.84× leverage (assets divided by equity) ≈ −39.2% on equity. The margin does its share; borrowing is a big part of it. ## Does Alamar Biosciences have too much debt? Alamar Biosciences, Inc. has total debt of $51.4 M against shareholder equity of $313 M as of Jun 2026, so its debt is 0.16× its equity, which is very little. Year by year, that ratio went from 0.33 in FY24 to 0.55 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Alamar Biosciences shareholding pattern? 6.4% of Alamar Biosciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Alamar Biosciences from balance-sheet trouble? For Alamar Biosciences, Inc., the Z-score is 12.10. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 12.10 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Alamar Biosciences rank in its industry? 38.8 out of 100, rank 30 of 30 in Medical Instruments & Supplies, with 28% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Alamar Biosciences, Inc. scores 38.8 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 30. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 21.6 + 4.7 + 12.5 = 38.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alamar Biosciences compared with? Alamar Biosciences ranks 30 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 38.8 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. Alamar Biosciences, Inc. this page ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/43.75 · Revenue n/a · Profit n/a · Operating margin change 3 points · 26% evidence Capital efficiency 4.7/31.25 · ROCE -11.7% · Operating margin -46% · 76% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 21.6 + 4.7 + 12.5 = 38.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Alamar Biosciences in size? Alamar Biosciences is the 24th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Pulse Biosciences, Inc., AtriCure, Inc. and Warby Parker Inc. Just below it: DENTSPLY SIRONA Inc., BioLife Solutions, Inc. and LeMaitre Vascular, Inc. ### Medical Instruments & Supplies companies close in size

1. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) $3.7 billion
2. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) $3.1 billion
3. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) $2.7 billion
4. Alamar Biosciences, Inc. $2.1 billion
5. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) $1.9 billion
6. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) $1.9 billion
7. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) $1.8 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Minerals Technologies Inc.](https://www.sectoralpha.in/us/stocks/mtx) $2 billion · Specialty Chemicals
2. [Sonic Automotive, Inc.](https://www.sectoralpha.in/us/stocks/sah) $2 billion · Auto & Truck Dealerships
3. Alamar Biosciences, Inc. $2 billion
4. [Pony AI Inc.](https://www.sectoralpha.in/us/stocks/pony) $2 billion · Information Technology Services
5. [Karooooo Ltd.](https://www.sectoralpha.in/us/stocks/karo) $2 billion · Software - Application

## What else do people ask about Alamar Biosciences? ### What is Alamar Biosciences's stock price today? Alamar Biosciences, Inc.'s stock price is $30.22. The whole company is worth $2.1 B on the market. In the last 52 weeks it traded between $20 to $35; today it is 69% of the way up from the low (as of 3 November 2026). ### What were Alamar Biosciences's latest quarterly results? Alamar Biosciences, Inc. reported revenue of $29.4 M and a net loss of $13.2 M for the Jun 2026 quarter. Earnings per share were −$0.22. The operating margin was −46.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Alamar Biosciences's market cap? Alamar Biosciences, Inc.'s market capitalisation is $2.1 B at a stock price of $30.22. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Alamar Biosciences performing? Alamar Biosciences, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Alamar Biosciences's stock price go up? This page does not forecast Alamar Biosciences, Inc.'s stock price. What it shows instead: the stock price is $30.22. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Alamar Biosciences have too much debt? No, Alamar Biosciences, Inc. has little debt: its debt is 0.14× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Alamar Biosciences in its business cycle? Alamar Biosciences, Inc.'s FY25 operating margin was −42.2%, against a 2-year range of −197.2% to −42.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −46.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Alamar Biosciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Alamar Biosciences a stock worth studying right now? What the numbers show: Alamar Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.